IN8bio Establishes Leadership in Gamma-Delta T Cell Therapy with Complete Remission in AML Patients and FDA Guidance for INB-100 Trial

NEW YORK, NY, USA I August 12, 2024 I IN8bio, Inc. (Nasdaq: INAB), a prominent clinical-stage biopharmaceutical firm specializing in pioneering gamma-delta T cell therapies for cancer, has recently shared updated positive clinical data from its Phase 1 investigator-sponsored trials. These trials include INB-100 for hematological malignancies and INB-200 for Glioblastoma Multiforme (GBM). Additionally, the Company has successfully concluded a Type B meeting with the FDA and acquired guidance on advancing INB-100 as a treatment for Acute Myeloid Leukemia (AML).

Remarkably, all AML patients treated with INB-100 are still in complete remission (CR), and participants across both trials have surpassed the anticipated progression-free survival (PFS) benchmarks. This data underscores the extensive clinical promise of gamma-delta T cells for challenging cancers and supports the progression of these therapies into Phase 2 trials.

As of August 1, 2024, there have been no new relapses since the previous clinical updates presented at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) annual meetings.

William Ho, CEO and co-founder of IN8bio, commented on these encouraging developments, stating, “Our gamma-delta T cell therapies, enhanced with our cutting-edge manufacturing technology, continue to exhibit their ability to eradicate residual cancer cells and potentially revolutionize cancer treatment.” He emphasized that the safety profile of gamma-delta T cells has been manageable and well-tolerated, with no significant cell therapy-related toxicities reported in any patient across both Phase 1 trials.

Program Details as of August 1, 2024:
- INB-100 for AML
- INB-200 for GBM

Ho added, “These therapies leverage gamma-delta T cells’ inherent capacity to address the heterogeneity of cancers, avert immune escape, and prevent disease relapse. Multiple patients have maintained progression-free remission beyond expectations, with many surpassing expected overall survival based on historical data. The safety profile and enduring remissions observed with both INB-100 and INB-200, now exceeding three years across two challenging indications, indicate a potentially significant advancement in cellular cancer therapies. Given these compelling results, IN8bio is at the forefront of innovation in oncology and gamma-delta T cell development.”

About IN8bio:
IN8bio is dedicated to developing gamma-delta T cell-based immunotherapies for cancer treatment. Gamma-delta T cells are a specialized subset of T cells that can distinguish between healthy and diseased tissues. IN8bio's leading program, INB-400, is currently in a Phase 2 trial for GBM. Other initiatives include Phase 1 trials for both solid and hematologic tumors, such as INB-200 for GBM and INB-100 for hematologic malignancies in transplantation patients.